Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEMMAT in Recurrent/Progressive Pediatric CNS Tumors
NCT01356290Phase 2Recruiting
- Sponsor
- Medical University of Vienna
- Start
- Apr 2014
- Primary completion
- Apr 2030
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of bevacizumab, thalidomide, celecoxib oral solution, fenofibric acid, etoposide in medulloblastoma, ependymoma, Atypical teratoid rhabdoid tumor (ATRT), central nervous system tumor, sponsored by Medical University of Vienna. Started Apr 2014; status: recruiting.
02
Drugs
bevacizumabthalidomidecelecoxib oral solutionfenofibric acidetoposide
03
Conditions
medulloblastomaependymomaAtypical teratoid rhabdoid tumor (ATRT)central nervous system tumor
Beyond the preview
Go deeper on NCT01356290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01356290.